Navigation Links
Hepatitis C Drug Market: Forecasts for 9 Countries, Players' (Current and Future) Analysis in New Research Reports
Date:6/13/2013

DALLAS, June 13, 2013 /PRNewswire-iReach/ -- RnRMarketResearch.com now offers new market research reports on the Hepatitis C Virus drug industry for US, Japan, Brazil China, France, Germany, Italy, Spain and the UK with an in-depth analysis on the companies in these countries. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche's Pegasys and Merck's PegIntron) and ribavirin (e.g., Roche's Copegus and Merck's Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck's Victrelis (boceprevir) or Vertex's Incivek (telaprevir).

(Photo: http://photos.prnewswire.com/prnh/20130613/CG31482)

In United States, the projected drivers of HCV drug market growth include increased patient awareness of HCV, broader HCV screening recommendations, the shift in American medicine toward preventative care, and the launch of next-generation HCV therapies. The report "PharmaPoint: Hepatitis C Virus – United States Drug Forecast and Market Analysis" (http://www.rnrmarketresearch.com/pharmapoint-hepatitis-c-virus-united-states-drug-forecast-and-market-analysis-market-report.html) says Vertex's Incivek is the current market leader. It was among the first DAA HCV therapies launched in the US. Incivek's improved efficacy over the previous standard of care (i.e., peginterferon and ribavirin combination therapy) in the treatment of the most prevalent HCV genotype in the US, HCV GT1, enabled the drug to quickly capture the market. The adverse events associated with Incivek therapy, such as life-threatening skin reactions, and the slow-progressing nature of HCV, has resulted in many patients deciding to forego treatment in order to wait for the launch of a more-tolerable HCV regimen.

Standard interferon drugs are the current market leader in China as per the report "PharmaPoint: Hepatitis C Virus – China Drug Forecast and Market Analysis" (http://www.rnrmarketresearch.com/pharmapoint-hepatitis-c-virus-china-drug-forecast-and-market-analysis-market-report.html). Primary research done for this report revealed that Merck's Intron A (interferon alfa-2b) is the most commonly prescribed standard interferon in China, but that Roferon-A (interferon alfa-2a) and Kadmon's Infergen (interferon alfacon-1) are also used frequently. Standard interferon requires more-frequent dosing than peginterferon alpha, but standard interferon has been able to retain its market share in China in the face of competition from peginterferon due to its lower cost.

The anticipated drivers of growth of the HCV market in Brazil include increasing awareness of the disease, the adoption of non-invasive liver diagnostic tests, and the launch of next-generation HCV therapies. The report "PharmaPoint: Hepatitis C Virus – Brazil Drug Forecast and Market Analysis" (http://www.rnrmarketresearch.com/pharmapoint-hepatitis-c-virus-brazil-drug-forecast-and-market-analysis-market-report.html) says Roche's Pegasys (peginterferon alfa-2a) is the current market leader in Brazil. Pegasys was launched in Brazil after Merck's PegIntron (peginterferon alfa-2b), but GlobalData believes that Pegasys was able to quickly dominate the market due to a perceived better side effect profile and efficacy. Sales of both Pegasys and PegIntron are projected to increase in Brazil as a result an increase in the country's HCV treatment rate. Sales of both drugs are also expected to be boosted by their drug's inclusion in triple therapies (i.e., DAA, peginterferon, and ribavirin).

"PharmaPoint: Hepatitis C Virus – Japan Drug Forecast and Market Analysis" (http://www.rnrmarketresearch.com/pharmapoint-hepatitis-c-virus-japan-drug-forecast-and-market-analysis-market-report.html) says Merck's PegIntron (peginterferon alfa-2b) is the current market leader in Japan. The current standard of HCV therapy in Japan is a combination of interferon and ribavirin. The less-frequent dosing of peginterferon compared with standard interferon (i.e., once a week compared with three times a week) enabled peginterferon to quickly capture market share. In addition to standard interferon, PegIntron directly competes for market share with Roche's Pegasys (peginterferon alfa-2a). GlobalData's primary research revealed that peginterferon market position is further bolstered by the frequent use of interferon monotherapy in Japan.

Janssen's Incivo is the current market leader in the UK Hepatitis C Virus drug market as per the report "PharmaPoint: Hepatitis C Virus – United Kingdom Drug Forecast and Market Analysis" @ http://www.rnrmarketresearch.com/pharmapoint-hepatitis-c-virus-united-kingdom-drug-forecast-and-market-analysis-market-report.html. Incivo was among the first DAA HCV therapies launched in the UK. The regimen had an improved efficacy compared with the previous standard of care for HCV GT1, a combination of peginterferon and ribavirin. GlobalData assumes that Incivo's shorter duration of triple-therapy (i.e., DAA, peginterferon, and ribavirin) compared with Merck's Victrelis enabled it to outcompete Victrelis for market share. Incivo and Victrelis are both associated with adverse events, which has resulted in HCV-infected patients in the UK deciding to forego therapy in order to await the launch of more-tolerable HCV therapies.

Other country reports available on the Hepatitis C Virus drug market forecasts:

On the same lines, a different but relevant report "PharmaPoint: Hepatitis C Virus – Current and Future Players" @ http://www.rnrmarketresearch.com/pharmapoint-hepatitis-c-virus-current-and-future-players-market-report.html is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing HCV Market. The report identifies and analyses the key companies shaping and driving the global HCV market. The report provides insight into the competitive HCV landscape, including new companies entering the market. Companies covered in this report include Merck, Roche, Vertex, Janssen, Gilead, AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, Mitsubishi Tanabe, GlaxoSmithKline, Achillion, Scynexis, Idenix and Presidio. Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=101454.

Explore more reports on the Hepatitis Drugs Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/hepatitis-drugs.

About Us:

RnRMarketResearch.com is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Explore more market research reports @ http://www.marketreportsstore.com/.

Media Contact: Priyank Tiwari RnR Market Research, +1 888 391 5441, sales@rnrmarketresearch.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE RnRMarketResearch.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
2. Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy
3. Bulgaria Launches Development of National Hepatitis Plan
4. Major Breakthrough in Hepatitis C Vaccine Development
5. Aethlon Medical Discusses Therapeutic Device Strategies to Address Cancer, Hepatitis-C and Sepsis with the Wall Street Transcript
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Aethlon Medical Receives Intent to Issue Notice on European Patent to Remove Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and Other Viral Pathogens From Blood
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
10. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
11. Computer Modeling Reveals How Surprisingly Potent Hepatitis C Drug Works
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016 Laboratory glassware ... in laboratories. These may range from microscope slides to ... is made from borosilicate glass because of its low ... the other hand, started gaining popularity over the past ... to replace glass with plastic in several applications due ...
(Date:2/11/2016)... -- Governor Andrew M. Cuomo today announced a major expansion ... Western New York . This announcement, made ... includes a major expansion of Athenex,s North American headquarters ... , as well as the creation of a state-of-the-art, ... . The combined projects are expected to yield ...
(Date:2/11/2016)... 11, 2016  NOIT™ Research LLC, a private, leading-edge ... Change" campaign to assist needy families in obtaining one ... sold between February 10, 2016 and March 31, 2016, ... family. The NOIT is an auditory stimulus that plays ... language skills. Beth Shier , NOIT ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... ... Clinical Data Management Solution Providers list for its expertise in eClinical Solutions. DDi ... expertise to serve the technology needs of global clients. DDi provides smarter technology ...
(Date:2/12/2016)... LA (PRWEB) , ... February 12, 2016 , ... The ... St. Landry and Evangeline Parishes. The purpose of these scholarships is to encourage ... encourage those individuals to seek employment within these two parishes. , “We have ...
(Date:2/12/2016)... ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , ... , As Winston Churchill said, “Those who don’t learn from history are doomed to ... expect when they come knocking this year. But that takes time. , Take a ...
(Date:2/12/2016)... ... February 12, 2016 , ... As a former television executive, ... demanding job, and no time to decompress, Rabinowitz found herself drawn to a casual ... for its impact on her life, implementing a 20-minute-per-day meditation practice with her team. ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ... Zuckerberg San Francisco General Hospital on April 5-7. The series is a multi-day, ... new habits. The workshops cover a broad range of topics, including coaching skills, ...
Breaking Medicine News(10 mins):